DOAC in Unusual Site Venous Thrombosis
Key facts
- Who runs it
- University of Malta
- Where
- Detroit, United StatesSee the siteAlso in 9 other countries, 23 sites
- Trial code
- Status
- Completed
- People taking part
- 358 people enrolled
- Started
- 1 Oct 2019
- Ended
- 31 Dec 2024
- Type of study
- Observational
- Treatments tested
- Direct Oral Anticoagulants
- Record updated
- 3 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs and pulmonary arteries
- Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)
Who cannot take part
- Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site VTE
Where in United States
Also in 9 other countries, 23 sites
- Henry Ford Health SystemDetroit, United States
About the trial
What the trial wants to find out
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.
Treatments tested
- Direct Oral Anticoagulants
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism
- Record updated
- 3 July 2025